Market Overview - The Hong Kong stock market exhibited a "structural differentiation" trend on February 10, with a strong wait-and-see sentiment before the holiday. The Hang Seng Index rose by 0.58% to 27,183.15 points, the Hang Seng Tech Index increased by 0.62% to 5,451.03 points, the National Enterprises Index climbed by 0.81% to 9,242.75 points, and the Red Chip Index gained 0.27% to 4,407.29 points [1] Individual Stock Highlights - Evergrande Property saw a significant increase of 5.36% to 1.18 HKD, driven by news of potential bidders submitting updated offers for the company's assets, indicating progress in the liquidation process [2] - The stock of Geekplus Technology surged by 11.37% to 28.02 HKD following the launch of its Gino 1 warehouse robot, which is expected to accelerate the adoption of unmanned warehouses [3] - Yiteng Jiahe rose nearly 7% due to the completion of the first dosing in Phase II clinical trials for its ANGPTL3 siRNA drug EDP167 [4] - Bubble Mart received a favorable outlook from Macquarie, with a reiterated "outperform" rating, projecting global sales to exceed 400 million units by 2025 [5] Sector Performance - The AI and robotics sector emerged as a strong focus, with multiple stocks experiencing significant gains, including MiniMax-WP and Zhiyuan, which saw increases of 24% and 11%, respectively [3] - Pharmaceutical and technology hardware stocks also showed positive performance, with notable gains from companies like Singularity and Gree Medical, benefiting from favorable policy changes and strategic investments [4] Institutional Insights - Dongwu Securities noted that despite increased inflows from southbound funds, overall trading volume in the Hong Kong market has decreased, influenced by global tech stock capital expenditure concerns [6] - Analysts from Jianyin International indicated that the valuation recovery of Hong Kong stocks is nearly complete, shifting the investment logic from "valuation recovery" to "new productive forces" [6] - Analysts emphasized that the continuous inflow of southbound funds could enhance market sentiment and strengthen the pricing power of mainland funds in the Hong Kong market [6]

恒生港股通创新药指数是ETF跟踪的指数中首批"纯度"达100%的创新药指数，精准汇聚港股创新药领军 企业；中证港股通医药卫生综合指数从港股通范围内选取医药卫生行业中市值较大的50只上市公司作为 样本，覆盖创新药、医疗器械等领域。投资者可通过港股通创新药ETF易方达（159316）、港股通医药 ETF易方达（513200）等跟踪上述指数的产品，精准捕捉医药产业发展机遇。 1月30日，石药集团与阿斯利康达成总额高达185亿美元的合作，首付款12亿美元，创下中国药企对外授 权交易新纪录。2月8日，信达生物与礼来达成88.5亿美元合作，首付3.5亿美元，创新采用"端到端共 研"模式。据统计，2026年以来创新药BD合作的首付款规模，已超越2025年全年最高单季度水平，总交 易金额已达332.8亿美元，产业出海势头迅猛。 同时，龙头公司业绩预告验证了高景气度。信达生物、荣昌生物与君实生物预告2025年营业收入分别约 为110亿元、32.5亿元和25亿元，同比大幅增长45%、89%和32%，强劲的业绩增长为板块提供了坚实的 基本面支撑。 2月10日，港股医药板块全天强势领涨，截至15:15，恒生港股通创新药指数上涨2.7 ...

Group 1 - The Hong Kong stock market is experiencing a rally, with both the Hang Seng Index and the Hang Seng Tech Index rising over 1% [1] - The AI application and innovative pharmaceutical sectors are leading the gains in the market [1] - Companies such as Yu Wen Group and Zhi Pu have seen their stock prices increase by over 6%, while Kangfang Biotech and Innovent Biologics have risen by over 3% [1]

Group 1 - The number of mainland private equity fund managers holding Hong Kong's Type 9 license has exceeded 130, marking an increase of over 40 compared to the same period last year, indicating a significant trend towards internationalization among mainland private equity firms [1] - As of November 2025, the total number of mainland private equity institutions holding the Type 9 license reached 107, and this number quickly rose to 135, reflecting a strong demand for global asset allocation among leading private equity firms [1] - Holding a Type 9 license signifies that these private equity firms have obtained legal qualifications to conduct regulated asset management business in Hong Kong, which plays a crucial role in enhancing the international competitiveness of Chinese private equity [1] Group 2 - The Hong Kong IPO market has been thriving, with institutional investors participating in cornerstone investments exceeding 30 billion HKD since the beginning of the year, including significant contributions from major mainland private equity firms and international funds [2] - Foreign institutions have made multiple increases in holdings in the Hong Kong stock market since 2026, with Morgan Stanley investing over 1 billion HKD in several listed companies, indicating that Hong Kong remains a key entry point for foreign capital into China [2] - The internationalization of mainland private equity is transitioning from a trial phase to a new cycle of global competition, with the growing number of licensed private equity firms signaling a new stage of high-quality development in the Chinese private equity industry [2]

2025年5月下旬，港股三生制药股价单日暴涨超30%，子公司三生国健在A股市场更是连续四个交易日 斩获"20CM"涨停。点燃这场资本狂欢导火索的，是一笔高达60.5亿美元的对外授权合作交易——辉瑞 拿下其抗癌双抗药物SSGJ-707海外权益，仅首付款就达到12.5亿美元。 而这，仅仅只是拉开了全年BD热潮的序幕。 从三生制药和辉瑞的双抗交易刷新国内BD首付款记录开始，信达生物、舶望制药、恒瑞医药 （600276）等公司接连宣布与武田、诺华、GSK等跨国药企达成数十亿乃至上百亿美元的合作。 过去一年，"BD"无疑是医药行业贯穿全年的核心关键词。据医药魔方研报数据披露，2025年国内创新 药对外授权交易总交易额超1300亿美元，仅首付款就超70亿美元，在ADC、双抗、GLP-1等前沿赛道 上，更是展现出影响细分赛道未来格局的潜力。 除了金额的飙升，BD交易模式的演变同样反映出产业关系的变迁。从单纯的licenseout到New-Co和Co- co模式（共同开发、共同商业化），乃至于共建"风险共担、利益共享"的生态，从单纯的"卖产 品"到"卖平台"，传统药企强势崛起，中小biotech多点开花。 刘立鹤同样提到，相 ...

港股通创新药ETF跟踪中证港股通创新药指数，指数编制方式更科学合理，成分股涵盖如百济神州、信达生物和药明生物等龙头企业。 港股通创新药ETF易方达是目前市场上唯一跟踪恒生港股通创新药指数的产品，该指数在编制方案中明确剔除了CXO公司，聚焦创新药产业核心企业，权重 股包括百济神州、信达生物、药明生物、康方生物等龙头公司，为投资者布局港股前沿创新药企提供了便捷工具。 港股创新药上涨，石药集团、药明生物、信达生物涨超5%，带动港股通创新药ETF嘉实、港股通创新药ETF万家、港股创新药50ETF、港股通创新药ETF鹏 华、港股创新药ETF、恒生生物科技ETF南方、港股通创新药ETF、港股创新药ETF、港股通创新药ETF南方、港股通创新药ETF工银、港股通创新药ETF、 恒生生物科技ETF易方达、 港股通医疗ETF富国上涨。 | 证券代码 | 证券简称 | 当日涨幅% | 年内涨幅 | 管理 | | --- | --- | --- | --- | --- | | 520970.SH | 港股通创新药ETF嘉实 | 3.27% | 11.03% | 嘉委 | | 520700.SH | 港股通创新药ETF万家 | 3.1 ...

从基本面看，创新药业绩预告验证产业景气。信达生物、荣昌生物和君实生物预告2025年收入约 110/32.5/25亿元，分别同比增长45%/89%/31.8% 国金证券认为，2-3月有望迎来创新药企业的业绩披露窗口，多家药企有望迎来减亏或扭亏，同时预计 2026年更多创新药企业有望扭亏并大幅释放利润；展望全年，AACR（4月）、ASCO（5月）、ESMO （10月）等学术会议上国产创新药有望进一步带来临床数据的兑现；整体上，创新药前期回调较为充 分，向上产业趋势明确，催化近期密集，继续看好板块投资机会。 港股创新药上涨，截至发稿，港股通创新药ETF易方达(159316)涨2.89%，港股通医药ETF易方达 (513200)涨2.33%。 板块反弹主要受BD交易密集落地、预告业绩高增及流动性改善三重利好驱动。 创新药重磅BD频出：石药集团×阿斯利康：1月30日达成185亿美元合作（首付12亿美元），创中国药企 BD纪录； 信达生物×礼来：2月8日达成88.5亿美元合作（首付3.5亿美元），采用"端到端共研"模式； 2026年以来创新药BD首付款规模已超25年全年最高单季度水平，总交易金额达332.8亿美元（占25 ...

Group 1 - The core viewpoint of the news highlights a rebound in innovative pharmaceuticals, with the Guotai Innovation Drug ETF (589720) rising over 2% and attracting nearly 500 million yuan in funds over the past 10 days, currently leading its peers with a total size exceeding 1.5 billion yuan [1] - Recent industry dynamics focus on multinational collaborations and domestic innovations, exemplified by the strategic partnership between Innovent Biologics and Eli Lilly to advance global R&D in oncology and immunology, with Innovent receiving an upfront payment of 350 million USD and potential milestone payments of up to 8.5 billion USD [1] - Additionally, Carl Zeiss announced the launch of its Greater China headquarters project in Shanghai, aimed at integrating and upgrading its core functions in management, R&D, and production to strengthen its innovation network in China [1] Group 2 - Bohai Securities noted that at the 2026 JPM Healthcare Conference, numerous Chinese pharmaceutical companies showcased their latest research achievements, and there has been a surge in large-scale business development (BD) activities, indicating active collaboration with multinational corporations (MNCs) [2] - The report suggests monitoring companies that may experience a bottoming out of performance as earnings forecasts are disclosed, while also highlighting the rapid development of brain-computer interfaces and AI applications, which are expected to benefit consumer-oriented companies amid domestic demand recovery [2] - The industry faces several risks, including geopolitical tensions, product development failures, expanded centralized procurement leading to price pressures, intense competition causing price declines, and significant increases in raw material costs [2]

Group 1 - The core viewpoint of the news highlights significant advancements in the biotech sector, particularly in the collaboration between Innovent Biologics and Eli Lilly, which focuses on new drug development in oncology and immunology, with a deal size exceeding expectations [1] - The collaboration employs a "China PoC + global development" model, leveraging Innovent's efficient clinical validation capabilities in China while utilizing Eli Lilly's global commercialization network to mitigate risks, marking a key step in the globalization of Chinese innovative pharmaceutical companies [1] - The assets involved in the collaboration, such as IBI363 and IBI343, have entered global multi-center Phase III clinical trials, with a combined potential market space of $60 billion [1] Group 2 - The ADC commercialization process is accelerating, with 20 ADC drugs approved globally, six of which have consistently been in the "billion-dollar club" for two years; approximately 60 are in Phase III clinical trials or awaiting market approval [2] - Local companies are increasingly gaining advantages due to their self-commercialization capabilities, as seen with Rongchang Biologics transitioning from outsourcing to in-house production, and Keren Biotechnology and Baillie Tianheng accelerating the establishment of their own production bases [2] - The Hong Kong Innovation Drug ETF has seen a strong performance, with a 3.10% increase as of February 10, 2026, and a total scale of 25.98 billion yuan, indicating a positive trend in investment within the sector [2]

2月10日早盘，港股市场创新药再度活跃，再鼎医药、信达生物、科伦博泰生物、药明生物、映恩 生物等领涨，恒生医药ETF（159892）盘中涨超2%。 消息面来看，信达生物近日宣布与礼来制药达成战略合作，携手推进肿瘤及免疫领域创新药物的全 球研发，首付款达3.5亿美元，里程碑付款有望达85亿美元。 东海证券表示，创新药板块靓丽的业绩表现，充分验证了国产创新药商业模式的有效性，医保加持 下的核心产品放量成为业绩增长基础，BD等对外合作则成为业绩增厚的重要抓手。 每日经济新闻 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com （责任编辑：张晓波 ） ...